Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars Will Get PDUFA-Style Reviews Under New User Fee Plan

Executive Summary

FDA will have a total of 12 months to review 351(k) applications and additional time to schedule certain product development meetings under the Biosimilar User Fee Act II agreement; measures to enhance management of user fee resources and improve hiring will carry over from PDUFA VI.

You may also be interested in...



FDA's Biosimilars Meeting Management Should Improve After Reorg In New Drug Office

US FDA met more biosimilar user fee program meeting performance goals in FY 2018 compared to prior year but still fell short in scheduling for three of five types of meetings. Office of New Drugs reorganization, once completed, should address some logistical scheduling issues.

Two Months To Add Two Words – Biosimilar Supplement Review Times May Be Hindering Uptake

Biosimilar supplement approvals by the US FDA take on average about five months as sponsors request easier and quicker ways to update labels.

US FDA's Patrick Frey Joins List Of Agency Leadership Departures

Office of New Drug's chief of staff will become Amgen's director of global regulatory policy and R&D.

Related Content

Topics

UsernamePublicRestriction

Register

PS119193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel